Impact of Spices and Herbs on Endothelial Function

NCT ID: NCT01085019

Last Updated: 2012-06-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

224 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-03-31

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The general objective of the study is to investigate the effects of the daily consumption of spices and herbs for four (4) consecutive weeks in endothelial function and cardiovascular risk factors of men and postmenopausal women.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose is to assess whether the polyphenol/antioxidant content of different spices will affect endothelial function and other cardiovascular risk factors.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endothelial Function

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dietary supplement: Cinnamon

Group Type EXPERIMENTAL

Cinnamon

Intervention Type DIETARY_SUPPLEMENT

2.8g/day of cinnamon in capsules during 4 weeks.

Dietary supplement: Oregano

Group Type EXPERIMENTAL

Oregano

Intervention Type DIETARY_SUPPLEMENT

2.8g/day of oregano in capsules during 4 weeks.

Dietary supplement: Ginger

Group Type EXPERIMENTAL

Ginger

Intervention Type DIETARY_SUPPLEMENT

2.8g/day of ginger in capsules during 4 weeks.

Dietary supplement: Rosemary

Group Type EXPERIMENTAL

Rosemary

Intervention Type DIETARY_SUPPLEMENT

2.8g/day of rosemary in capsules during 4 weeks.

Dietary supplement: Black pepper

Group Type EXPERIMENTAL

Black pepper

Intervention Type DIETARY_SUPPLEMENT

2.8g/day of black pepper in capsules for 4 weeks.

Dietary supplement: Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

2.8 g/day of placebo in capsules (corn starch) during 4 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cinnamon

2.8g/day of cinnamon in capsules during 4 weeks.

Intervention Type DIETARY_SUPPLEMENT

Oregano

2.8g/day of oregano in capsules during 4 weeks.

Intervention Type DIETARY_SUPPLEMENT

Ginger

2.8g/day of ginger in capsules during 4 weeks.

Intervention Type DIETARY_SUPPLEMENT

Rosemary

2.8g/day of rosemary in capsules during 4 weeks.

Intervention Type DIETARY_SUPPLEMENT

Black pepper

2.8g/day of black pepper in capsules for 4 weeks.

Intervention Type DIETARY_SUPPLEMENT

Placebo

2.8 g/day of placebo in capsules (corn starch) during 4 weeks.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 40-70 yrs
* Men and postmenopausal women
* Waist girth \>102cm (men) or \>88cm (women)
* LDL-C \> 2.8 mmol/L
* Framingham 10-yr risk score \< 10%
* Marginal endothelial dysfunction
* Non smoker

Exclusion Criteria

* Medication for lipid, hypertension, diabetes
* History of CVD, diabetes, other endocrines disorders
* Pre-menopausal women
* Alcohol consumption \> 1 drink per day
* Unusual dietary habits (e.g. vegetarism)
* Chronic use of supplements (estrogens, vitamins, minerals or flavonoids)
* Aversion or intolerance for spices and/or herbs
* Injury to fingers or amrs that would interfere with endothelial function measurement
Minimum Eligible Age

40 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

McCormick Canada Co

UNKNOWN

Sponsor Role collaborator

Laval University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Charles Couillard

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Charles Couillard, Ph.D

Role: PRINCIPAL_INVESTIGATOR

Laval University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Richardson Centre of Functional Foods and Nutracuticals

Winnipeg, Manitoba, Canada

Site Status

Institute of Nutraceuticals and Functional Foods

Québec, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

References

Explore related publications, articles, or registry entries linked to this study.

Carnovale V, Paradis ME, Gigleux I, Ramprasath VR, Couture P, Jones PJ, Lamarche B, Couillard C. Correlates of reactive hyperemic index in men and postmenopausal women. Vasc Med. 2013 Dec;18(6):340-6. doi: 10.1177/1358863X13507975.

Reference Type DERIVED
PMID: 24292639 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

INAF-2009-253

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effects of Curcumin on Vascular Reactivity
NCT01543386 COMPLETED PHASE1/PHASE2